Mektovi (Binimetinib) Patent Expiration, LOE Window & CMS Spending

Mektovi (Binimetinib) by Pfizer: FDA Orange Book core substance LOE 2033-10-18, 0 AB generics, $114.8M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN210498 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-10-18
Last Listed Patent or Exclusivity Date2033-10-18
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$114.8M
2024 Medicare Part D Spend$96.2M
2024 Medicaid Spend$18.6M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 25.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.